Merck & Co (NY: MRK )

80.44 USD -0.71 (-0.87%)

Streaming Delayed Price Updated: 9:59 AM EST, Jan 26, 2021 Add to My Watchlist

Price and Volume

Volume	647,762
Open	81.15
Bid (Size)	80.44 (3)
Ask (Size)	80.46 (2)
Prev. Close	81.15
Today's Range	80.13 - 81.15
52wk Range	65.25 - 89.20
Shares Outstanding	2,690,303,898
Dividend Yield	2.39%

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021

Today 9:06 EST

Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P

European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal

Today 6:45 EST

European Commission Approves KEYTRUDA as First-Line Treatment in Adult Patients With Metastatic MSI-H or dMMR Colorectal Cancer

Performance

YTD	-0.64%	-0.64%
1 Month	-0.01%	-0.01%
3 Month	+2.03%	+2.03%
6 Month	+1.92%	+1.92%
1 Year	-6.57%	-6.57%

More News

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

January 25, 2021

Merck Just Scrapped Its Coronavirus Vaccines — Is Merck Stock A Buy?

Today 7:00 EST

Warren Buffett's 3 Biggest Stock Picks for 2021

Today 5:46 EST

ROCE Insights For Merck & Co

January 25, 2021

Biden to reinstate travel bans amid fears about new variants as global case tally heads toward 100 million

January 25, 2021

Merck Gives Up on Coronavirus Vaccines

January 25, 2021

Dow Pares Big Loss, Nasdaq Hits New High As Apple Stock Rallies Ahead Of Earnings

January 25, 2021

Thinking about trading options or stock in Niu Technologies, Regeneron Pharmaceuticals, General Electric, Merck, or Axon Enterprise?

January 25, 2021

Merck Drops COVID-19 Vaccine Studies After Phase 1 Data Churn Out Inferior Efficacy Results

January 25, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.